Headline: Zerva acquires Acer Therapeutics to bolster rare disease portfolio
Acquiror: Zerva Therapeutics
Target: Acer Therapeutics
Target Services: Rare therapies portfolio
Country: United States
Continent: North America
Target Industry: Pharmaceuticals
Rationale: Strengthens Zerva’s rare disease portfolio through the acquisition of Acer Therapeutics and gaining rights to the FDA-approved rare drug Olpruva.
Summary: Zerva Therapeutics acquires Acer Therapeutics to enhance its rare disease portfolio, including the FDA-approved drug Olpruva.